Product nameAnti-Endothelin A Receptor/ET-A antibody
See all Endothelin A Receptor/ET-A primary antibodies
DescriptionRabbit polyclonal to Endothelin A Receptor/ET-A
Tested applicationsSuitable for: WB, ELISA, ICC/IF, IHC-Pmore details
Species reactivityReacts with: Human, African green monkey
Predicted to work with: Mouse
- LOVO cells. Extracts from COS-7 cells.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab76259 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Predicted molecular weight: 49 kDa.|
|ICC/IF||1/500 - 1/1000.|
|IHC-P||Use a concentration of 4 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
FunctionReceptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.
Tissue specificityIsoform 1, isoform 3 and isoform 4 are expressed in a variety of tissues, with highest levels in the aorta and cerebellum, followed by lung, atrium and cerebral cortex, lower levels in the placenta, kidney, adrenal gland, duodenum, colon, ventricle and liver but no expression in umbilical vein endothelial cells. Within the placenta, isoform 1, isoform 2, isoform 3 and isoform 4 are expressed in the villi and stem villi vessels.
Sequence similaritiesBelongs to the G-protein coupled receptor 1 family. Endothelin receptor subfamily. EDNRA sub-subfamily.
Cellular localizationCell membrane.
- Information by UniProt
- Ednra antibody
- EDNRA_HUMAN antibody
- Endothelin 1 receptor precursor antibody
All lanes : Anti-Endothelin A Receptor/ET-A antibody (ab76259) at 1/500 dilution
Lane 1 : Extracts from COS-7 cells
Lane 2 : Extracts from COS-7 cells plus 5µg immunizing peptide
Lysates/proteins at 5 µg per lane.
Predicted band size: 49 kDa
Observed band size: 49 kDa
Immunofluorescence analysis of LOVO cells using ab76259 at a 1/500 dilution.
Left image un-treated.
Right image treated with immunizing peptide.
ab76259 (4µg/ml) staining Endothelin A/ET-A receptor in human cerebellum using an automated system (DAKO Autostainer Plus). Using this protocol there is strong staining of the endothelium.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer EDTA pH 9.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
ab76259 has been referenced in 4 publications.
- Ladd MR et al. The Development of Newborn Porcine Models for Evaluation of Tissue-Engineered Small Intestine. Tissue Eng Part C Methods 24:331-345 (2018). PubMed: 29638197
- Lupp A et al. Reassessment of endothelin receptor A expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-8. Peptides 66:19-25 (2015). IHC-P ; Human . PubMed: 25708416
- Irani S et al. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics. Ann Diagn Pathol 18:43-8 (2014). IHC-P ; Human . PubMed: 24332749
- Laurberg JR et al. High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. BMC Cancer 14:638 (2014). WB, IHC-P ; Human . PubMed: 25175477